BioPhorum Connect

Designing Drug Delivery Devices: Prioritizing Simplicity, Empathy, and Real Patient NeedsDescription / Show notes: Andy discusses the importance of patient-centered design in drug delivery devices, emphasizing that simplicity, reliability, and empathy should guide innovation rather than adding unnecessary features. Andy shares insights from his experience in human factors and medical design, highlighting the challenges patients face with complex therapies and the need to design devices that fit seamlessly into their lives. The conversation covers the pitfalls of overcomplicated devices, the myth of patient engagement, and the tension between regulatory requirements and true user needs, with examples illustrating how usability can be compromised by commercial or regulatory pressures.Patient-Centered Design: Understanding real patient needs and lifestyles is crucial, and devices should be designed to minimize cognitive load and fit into daily routines.Simplicity Over Complexity: Reliability and simplicity are more valuable to patients than flashy features, especially for those managing multiple therapies.Challenges with Existing Therapies: Older, complex drug reconstitution processes persist due to regulatory grandfathering, leading to frequent user errors. Engagement Myth: Debunking the idea that patients are excited about therapies, explaining that adherence is more about convenience than engagement. Regulatory vs. User Needs: The discussion highlights how some device features are added to meet regulatory or commercial goals, not actual patient benefit, sometimes increasing complexity without improving usability.

In this episode of BioPhorum Connect, host Loic Bishop speaks with Dr. Steven Levine, Senior Director of Life Sciences and Healthcare at Dassault Systèmes and Executive Director of the Living Heart Project. They explore how engineering principles and digital twin technology are reshaping the future of medicine—from personalised treatment planning to regulatory-grade simulations.Steven shares his personal journey, including how his daughter's congenital heart condition and a brain tumour has inspired him to pioneer a new approach to medical modelling. Learn how the Living Heart Project grew from a bold idea into a global collaboration involving over 165 organisations, and how it’s now influencing how we run clinical trials, regulatory processes, and the development of digital organs.Topics include:The origins and impact of the Living Heart ProjectBuilding a fully functioning digital heartCollaboration with the FDA and global regulatorsThe future of digital twins in drug development and personalised care

Rick Wedge shares his personal and professional journey from developing medical devices to becoming a patient dependent on diabetes technology, following a total pancreatectomy and diagnosis of Type 3C diabetes.The discussion covers the challenges of managing diabetes, the importance of wearables and continuous glucose monitoring, and the impact of technology on quality of life. Rick reflects on how his experience as a patient has deepened his perspective on risk management and device design, emphasizing the real-world implications for patients. The episode also explores future improvements for diabetes devices and the value of patient-centric innovation.

This AI-generated conversation explores the challenges of implementing AI in pharma accurately, reliably and safely, particularly given the stringent requirements of good practice (GxP) regulations and the need to enhance trust among stakeholders, including regulatory authorities, healthcare professionals, and patients. It is based on the BioPhorum publication Implementing AI systems in regulated pharma environments and key takeaways include: The whole AI lifecycle needs to be managed It's a risk-based approach with risk management throughout Setting clear objectives and scope creates the essential focus for success For reliable AI, data needs to be really well managed Algorithm selection and model design needs discipline to create assurance Deployment is about thinking of the whole system, which could include many AIs Data drifts, so ongoing monitoring and evaluation is essential Change control includes a much bigger challenge of version management You can also watch a 90-min webinar replay by nine of the (real-life) authors who illustrate each point from their experience.

In this episode of BioPhorum connect, we explore the newly published ASTM International standard guide 'Guide for Minimizing the impact of stability testing on batch yield of low yield biopharmaceutical products.'This guide, authored by BioPhorum members, builds on a foundational BioPhorum publication developed through collaboration among 12 companies in the Advanced Therapy Medicinal Products (ATMP) space, particularly focused on gene therapies.Simon Walker, Global Change Facilitator at BioPhorum, is joined by two key contributors to both the original BioPhorum deliverable and the ASTM guide:Gael Debauve, Head of Gene Therapy Analytical Sciences at UCBMadison Lee, Associate Director of CMC Program Management at RegeneronTogether, they discuss:Why minimizing the impact of stability testing is critical for low-yield productsHow the ASTM International guide expands the scope beyond gene therapiesThe value of using a mock gene therapy product to quantify potential savingsWho in the industry will benefit most from this guidanceThe collaborative advantage of working through BioPhorumWhether you're in QC, QA, regulatory affairs, or CMC leadership, this episode offers valuable insights into improving efficiency and conserving product in early-stage development.